Early diagnosis of mild cognitive impairment and Alzheimer's disease based on salivary lactoferrin

Introduction: The Alzheimer's disease (AD) process is likely initiated many years before clinical onset. Biomarkers of preclinical disease are critical for the development of disease-modifying or even preventative therapies. Current biomarkers for early disease, including cerebrospinal fluid ta...

Full description

Bibliographic Details
Authors: Carro, Eva, Bartolomé, Fernando, Bermejo-Pareja, Félix, Villarejo-Galende, Alberto, Molina, José Antonio, Ortiz, Pablo, Calero, Miguel, Rábano, Alberto, Cantero, José Luis, Orive, Gorka
Format: article
Publication Date:2017
Country:España
Institution:Instituto de Salud Carlos III (ISCIII)
Repository:Repisalud
Language:English
OAI Identifier:oai:repisalud.isciii.es:20.500.12105/10608
Online Access:http://hdl.handle.net/20.500.12105/10608
Access Level:Open access
Keyword:Diagnosis
Dementia
Mild cognitive impairment
Alzheimer’s disease
Lactoferrin
Saliva
Noninvasive biomarker
id ES_86d2affeddb5cf22c352f5692b08c838
oai_identifier_str oai:repisalud.isciii.es:20.500.12105/10608
network_acronym_str ES
network_name_str España
repository_id_str
spelling Early diagnosis of mild cognitive impairment and Alzheimer's disease based on salivary lactoferrinCarro, EvaBartolomé, FernandoBermejo-Pareja, FélixVillarejo-Galende, AlbertoMolina, José AntonioOrtiz, PabloCalero, MiguelRábano, AlbertoCantero, José LuisOrive, GorkaDiagnosisDementiaMild cognitive impairmentAlzheimer’s diseaseLactoferrinSalivaNoninvasive biomarkerIntroduction: The Alzheimer's disease (AD) process is likely initiated many years before clinical onset. Biomarkers of preclinical disease are critical for the development of disease-modifying or even preventative therapies. Current biomarkers for early disease, including cerebrospinal fluid tau and amyloid β (Aβ) levels, structural and functional magnetic resonance imaging, and the use of brain amyloid imaging, are limited because they are very invasive or expensive. Noninvasive biomarkers may be a more accessible alternative, but none can currently detect preclinical AD with the required sensitivity and specificity. Methods: Here, we show a novel, straight-forward, and noninvasive approach for assessment of early stages of cognitive decline. Salivary samples from cases of amnestic mild cognitive impairment (aMCI) and AD, and neurology controls were analyzed. Results: We have discovered and validated a new single saliva biomarker, lactoferrin, which in our cross-sectional investigation perfectly discriminates clinically diagnosed aMCI and AD patients from a cognitively healthy control group. The accuracy for AD diagnosis shown by salivary lactoferrin was greater than that obtained from core cerebrospinal fluid (CSF) biomarkers, including total tau and CSF Aβ42. Furthermore, salivary lactoferrin can be used for population screening and for identifying those underdiagnosed subjects with very early stages of mild cognitive impairment and AD. Conclusion: This biomarker may offer new insights in the early diagnostics for AD.Elsevier20202020-06-2920172017-01-0120172017-01-01research articlehttp://purl.org/coar/resource_type/c_2df8fbb1AMhttp://purl.org/coar/version/c_ab4af688f83e57aainfo:eu-repo/semantics/articleapplication/pdfhttp://hdl.handle.net/20.500.12105/10608reponame:Repisaludinstname:Instituto de Salud Carlos III (ISCIII)Inglésengopen accesshttp://purl.org/coar/access_right/c_abf2Attribution-NonCommercial-NoDerivatives 4.0 Internacionalhttp://creativecommons.org/licenses/by-nc-nd/4.0/info:eu-repo/semantics/openAccessoai:repisalud.isciii.es:20.500.12105/106082026-06-12T12:43:37Z
dc.title.none.fl_str_mv Early diagnosis of mild cognitive impairment and Alzheimer's disease based on salivary lactoferrin
title Early diagnosis of mild cognitive impairment and Alzheimer's disease based on salivary lactoferrin
spellingShingle Early diagnosis of mild cognitive impairment and Alzheimer's disease based on salivary lactoferrin
Carro, Eva
Diagnosis
Dementia
Mild cognitive impairment
Alzheimer’s disease
Lactoferrin
Saliva
Noninvasive biomarker
title_short Early diagnosis of mild cognitive impairment and Alzheimer's disease based on salivary lactoferrin
title_full Early diagnosis of mild cognitive impairment and Alzheimer's disease based on salivary lactoferrin
title_fullStr Early diagnosis of mild cognitive impairment and Alzheimer's disease based on salivary lactoferrin
title_full_unstemmed Early diagnosis of mild cognitive impairment and Alzheimer's disease based on salivary lactoferrin
title_sort Early diagnosis of mild cognitive impairment and Alzheimer's disease based on salivary lactoferrin
dc.creator.none.fl_str_mv Carro, Eva
Bartolomé, Fernando
Bermejo-Pareja, Félix
Villarejo-Galende, Alberto
Molina, José Antonio
Ortiz, Pablo
Calero, Miguel
Rábano, Alberto
Cantero, José Luis
Orive, Gorka
author Carro, Eva
author_facet Carro, Eva
Bartolomé, Fernando
Bermejo-Pareja, Félix
Villarejo-Galende, Alberto
Molina, José Antonio
Ortiz, Pablo
Calero, Miguel
Rábano, Alberto
Cantero, José Luis
Orive, Gorka
author_role author
author2 Bartolomé, Fernando
Bermejo-Pareja, Félix
Villarejo-Galende, Alberto
Molina, José Antonio
Ortiz, Pablo
Calero, Miguel
Rábano, Alberto
Cantero, José Luis
Orive, Gorka
author2_role author
author
author
author
author
author
author
author
author
dc.contributor.none.fl_str_mv
dc.subject.none.fl_str_mv Diagnosis
Dementia
Mild cognitive impairment
Alzheimer’s disease
Lactoferrin
Saliva
Noninvasive biomarker
topic Diagnosis
Dementia
Mild cognitive impairment
Alzheimer’s disease
Lactoferrin
Saliva
Noninvasive biomarker
description Introduction: The Alzheimer's disease (AD) process is likely initiated many years before clinical onset. Biomarkers of preclinical disease are critical for the development of disease-modifying or even preventative therapies. Current biomarkers for early disease, including cerebrospinal fluid tau and amyloid β (Aβ) levels, structural and functional magnetic resonance imaging, and the use of brain amyloid imaging, are limited because they are very invasive or expensive. Noninvasive biomarkers may be a more accessible alternative, but none can currently detect preclinical AD with the required sensitivity and specificity. Methods: Here, we show a novel, straight-forward, and noninvasive approach for assessment of early stages of cognitive decline. Salivary samples from cases of amnestic mild cognitive impairment (aMCI) and AD, and neurology controls were analyzed. Results: We have discovered and validated a new single saliva biomarker, lactoferrin, which in our cross-sectional investigation perfectly discriminates clinically diagnosed aMCI and AD patients from a cognitively healthy control group. The accuracy for AD diagnosis shown by salivary lactoferrin was greater than that obtained from core cerebrospinal fluid (CSF) biomarkers, including total tau and CSF Aβ42. Furthermore, salivary lactoferrin can be used for population screening and for identifying those underdiagnosed subjects with very early stages of mild cognitive impairment and AD. Conclusion: This biomarker may offer new insights in the early diagnostics for AD.
publishDate 2017
dc.date.none.fl_str_mv 2017
2017-01-01
2017
2017-01-01
2020
2020-06-29
dc.type.none.fl_str_mv research article
http://purl.org/coar/resource_type/c_2df8fbb1
AM
http://purl.org/coar/version/c_ab4af688f83e57aa
dc.type.openaire.fl_str_mv info:eu-repo/semantics/article
format article
dc.identifier.none.fl_str_mv http://hdl.handle.net/20.500.12105/10608
url http://hdl.handle.net/20.500.12105/10608
dc.language.none.fl_str_mv Inglés
eng
language_invalid_str_mv Inglés
language eng
dc.rights.none.fl_str_mv open access
http://purl.org/coar/access_right/c_abf2
Attribution-NonCommercial-NoDerivatives 4.0 Internacional
http://creativecommons.org/licenses/by-nc-nd/4.0/
dc.rights.openaire.fl_str_mv info:eu-repo/semantics/openAccess
rights_invalid_str_mv open access
http://purl.org/coar/access_right/c_abf2
Attribution-NonCommercial-NoDerivatives 4.0 Internacional
http://creativecommons.org/licenses/by-nc-nd/4.0/
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Elsevier
publisher.none.fl_str_mv Elsevier
dc.source.none.fl_str_mv reponame:Repisalud
instname:Instituto de Salud Carlos III (ISCIII)
instname_str Instituto de Salud Carlos III (ISCIII)
reponame_str Repisalud
collection Repisalud
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869412402076844032
score 15.811543

Similar Items